Targeted therapy in the treatment of solid tumors: Practice contradicts theory |
| |
Authors: | N V Zhukov S A Tjulandin |
| |
Institution: | Federal Research-Clinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health Care and Social Security of the Russian Federation, Moscow, 117997, Russia. zhukov.nikolay@rambler.ru. |
| |
Abstract: | The basic principle of targeted therapy formulated about ten years ago consists in the design and application of drugs specifically directed against well-defined targets that are critical for tumor survival and not compromising for normal organs and tissues. The past decade has been marked by the appearance of an immense diversity of novel antitumor agents with claimed targeted action. Unfortunately, despite indisputable progress in clinical settings, some popular drugs against solid tumors (e.g. bevacizumab, trastuzumab, erlotinib, gefitinib) nominally assigned to targeted-action drugs, cannot actually be classified with this group being nonconforming to a priori stated goals of targeted therapy. The state-of-the-art and current problems in targeted therapy of solid tumors are reviewed. |
| |
Keywords: | targeted therapy breast cancer colorectal cancer VEGF VEGFR EGFR HER-2 |
本文献已被 PubMed SpringerLink 等数据库收录! |
|